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Introduction
Nanoparticles (NPs) have specific physicochemical 
properties differing from bulk materials of the same 
composition, and such properties make them very attrac-
tive for commercial and medical development (Curtis 
et al., 2006; Lanone & Boczkowski, 2006; Medina et al., 
2007). However, compared with conventional materials, 
NPs may have differential toxicity profiles due to their 
different chemical and structural properties (Vega-Villa 
et al., 2008). For example, the interaction between nano-
materials and biological components, e.g. proteins and 
cells may lead to their unique bio-distribution, clearance, 
immune response, and metabolism, and therefore it is 
very necessary to study the in vivo toxicity of nanomateri-
als (Fischer & Chan, 2007).
Pullulan, a very important neutral and linear natural 
polysaccharide, has been used as a good biomaterial in 
drug and gene delivery, tissue engineering, and other 
fields (Leathers, 2003; Shingel, 2004; Rekha & Sharma, 
2007). Many investigations (Akiyoshi et al., 1993; Jeong 
et al., 2006) have reported that some hydrophobized 
pullulan such as cholesterol-modified pullulan can 
form self-aggregated NPs to be used as the carrier for 
drug delivery. As one of the most conventional hydro-
phobized pullulan derivatives (Jung et al., 2003; Na et al., 
2003; 2004, Park et al., 2007), pullulan acetate (PA) and 
its modified materials can form self-aggregated NPs in 
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Abstract
To develop pullulan acetate nanoparticles (PANs) as a drug nanocarrier, pullulan acetate (PA) was synthesized 
and characterized. Its acetylation degree determined by the proton nuclear magnetic resonance (1H NMR) 
was 2.6. PANs were prepared by the solvent diffusion method and characterized by transmission electron 
microscope (TEM), size distribution, and ζ potential techniques. PANs had nearly spherical shape with a size 
range of 200–450 nm and low ζ potentials both in distilled water and in 10% FBS. The storage stability of PANs 
was observed in distilled water. PANs were stored for at least 2 months with no significant size and ζ potential 
changes. The safety of PANs was studied through single dose toxicity test in mice, and the result showed that 
PANs were well tolerated at the dose of 200 mg/kg in mice. Epirubicin-loaded PANs (PA/EPI) were also prepared 
and characterized in this study. Moreover, the in vivo pharmacokinetics of PA/EPI was investigated. Compared 
with the free EPI group, the PA/EPI group exhibited higher plasma drug concentration, longer half-life time 
(t
1/2
) and the larger area under the curve (AUC). All results suggested that PANs were stable, safe, and showed 
a promising potential on improving the bioavailability of the loaded drug of the encapsulated drug.
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aqueous media. The hydrophobic core of these self-
assembled NPs formed by the hydrophobic interactions 
was considered to act as a reservoir of hydrophobic 
substances. In our previous report (Zhang et al., 2009), 
PANs prepared by the solvent diffusion method had the 
potential to be used as a sustained release carrier for 
Epirubicin (EPI) in vitro. Some investigations (Gu et al., 
1998; Na et al., 2004; Shimizu et al., 2008) showed that 
NPs of hydrophobized pullulans had good morphol-
ogy, drug loading, and release properties in vitro, but 
the biological effects of hydrophobized pullulan NPs 
in vivo have not been investigated deeply up to date. 
Herein, based on our previous work, we studied the 
stability and toxicity of PANs, and further investigated 
the sustained release behavior in vivo of drug loading in 
PANs. PA was firstly synthesized and characterized by 
FT-IR and 1H NMR, and then PANs with moderate size 
and low potential were prepared by the solvent diffusion 
method. The storage stability of PANs was studied in the 
aqueous medium, and the acute toxicity of PANs was 
evaluated in mice. Morever, EPI was loaded into PANs 
and its pharmacokinetics was also assessed in rats to 
compare to the free drug.
Methods
Materials
Pullulan (Mw = 200,000) was purchased from Hayashibara 
(Tokyo, Japan). Epirubicin·HCl (EPI·HCl) was purchased 
from Hisun Pharmaceutical Co. (Zhejiang, China). Poly 
(vinyl alcohol) (PVA) with an average molecular weight 
of 30,000–70,000 was obtained from Sigma-Aldrich (St. 
Louis, MO). All reagents for high performance liquid 
chromatography (HPLC) analysis, including acetonitrile 
and methanol, were HPLC grade. Other chemical reagents 
were of analytical grade and obtained from commercial 
sources. ICR mice and Wistar rats were purchased from 
the Institute of Radiology, Chinese Academy of Medical 
Science. All animal experiments were performed in 
compliance with the Institutional Animal Care and Use 
Committee (IACUC) guidelines.
Synthesis and characterization of PA
PA was synthesized according to the method described 
in previous literature (Jung et al., 2003; Zhang et al., 
2009). Briefly, pullulan (2 g) was suspended in 20 ml of 
formamide and dissolved by vigorous stirring at 54°C. 
Pyridine (6 ml) and acetic anhydride (5.5 ml) were added 
to the above solution, and the mixture was subsequently 
stirred at 54°C for 48 h. The reactant was precipitated with 
distilled water, and then washed with distilled water and 
methanol. The solid material was vacuum-dried at 50°C 
for 48 h. The final product was identified by Fourier trans-
form infrared (FT-IR) (Thermo, Nicolet is10, Los Angeles, 
CA ) and 1H NMR (Varian, Varian INOVA. 400 M NMR, 
Palo Alto, CA) spectrometry. The degree of substitution 
(DS) was defined as the number of acetyl groups per 
glucose unit of pullulan. It was determined by 1H NMR 
(Zhang et al., 2009). The DS values are expressed by the 
following equations: DS = 10A/(3B + A), where A is the 
integration value of acetyl protons at 1.8–2.2 ppm and B 
is that of OH protons and H-1 to H-6 protons of pullulan 
moiety observed at more than 3.5 ppm.
Preparation and characterization of PANs and PA/EPI
Nanoparticles were prepared according to a solvent dif-
fusion method (Fessi et al., 1989; Govender et al., 1999; 
Bilati et al., 2005; Zhang et al., 2009). Briefly, PA (100 mg) 
was dissolved in 10 ml of N, N-Dimethylformamide 
(DMF). The solution was then added to 0.5% PVA 
aqueous solution through a syringe under moderate 
magnetic stirring. The produced PANs were collected 
with centrifugation (Beckman Coulter, Inc. Avanti 
J-25, Fullerton, CA) at 18,000 rpm for 15 min at 4°C. 
Subsequently, PANs were dispersed in the distilled 
water and 10% fetal bovine serum (FBS), respectively, 
with PA concentration of 1 mg/ml to carry out the later 
experiments.
EPI-loaded PANs were prepared as follows: EPI·HCl 
(10 mg) was dissolved in DMF (2 ml) and then triethyl-
amine (TEA) was added to this solution to remove 
hydrochloride. The mixed solution was stirred in the 
dark for 12 h. PA (100 mg) dissolved in 8 ml of DMF 
was added into this mixed solution. The PA/EPI were 
collected with centrifugation (Beckman Coulter, Inc. 
Avanti J-25, Fullerton, CA) at 18,000 rpm for 15 min at 
4°C, then the supernatant removed and washed twice 
with distilled water, at last, dispersed in distilled water 
by sonication for several minutes with a probe-type 
sonifier (Automatic Ultrasonic Processor UH-500A, 
China) at 100 W.
The particle size and ζ potential were determined 
by dynamic light scattering (Malvern Instruments Ltd., 
Zeta sizer 2000, Worcestershire, UK). The morphology 
of NPs was observed using TEM (FEI, TECNAI G2F-20, 
Eindhoven, Holland).
The stability of PANs in water
In order to study the stability of PANs, the above disper-
sions were stored for 2 months at 4°C. Macroscopic char-
acteristics of NPs dispersions such as opalescence and 
precipitation were observed from time to time. Moreover, 
the size and ζ potential of PANs were also determined by 
dynamic light scattering method once a month, and all 
measurements were performed in triplicate.
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In vivo toxicity
The toxicity of PANs was evaluated in vivo according to 
the previous reported method (Yoksan & Chirachanchai, 
2008; Sonaje et al., 2009). Adult male and female ICR mice 
(18–22 g) were randomly divided into two groups, each 
with 10 mice. The experimental group received a single 
intravenous (i.v.) dose of blank PANs (200 mg/kg); the 
other group was treated with a single i.v. dose of normal 
saline. All animals were fed with normal diet, and water 
was provided ad libitum. Animals were observed care-
fully for the onset of any signs of toxicity and monitored 
for changes in food intake and body weight at 1, 8, and 
15 days. After being sacrificed at 15 days, internal organs 
of each animal were harvested and observed grossly. For 
histological examinations, specimens of major organs 
such as heart, liver, spleen, lung, and kidney were fixed 
in 10% phosphate buffered formalin, embedded in paraf-
fin, sectioned, and stained with hematoxylin and eosin 
(H&E).
In vivo pharmacokinetics and bioavailability
In vivo pharmacokinetic study was conducted by the 
routine method (Mross et al., 1988; Bibby et al., 2005; 
Cao & Feng, 2008; Devalapally et al., 2008). The drug 
content of the PA/EPI was determined according to 
our previous study (Zhang et al., 2009) and PA/EPI with 
3.34% was selected to carry out the pharmacokinetics 
studies. Female Wistar rats of 180~250 g and 4~6 weeks 
old were held in an air-conditioned facility, provided 
with standard food and filtered water. Animals were ran-
domly assigned to two groups, each with six rats, which 
received an i.v. injection via the tail vein of free EPI and 
the PA/EPI solution in saline at 10 mg/kg equivalent 
dose, respectively. All animals were observed for mortal-
ity, general condition, and potential clinical signs.
The blood samples were collected with heparinized 
tube at 0 (pre-dose), 0.0167, 0.0833, 0.167, 0.5, 1, 2, 4, 8, 
12, 24, and 48 h post-treatment. Plasma samples were 
harvested by centrifugation at 3000 rpm for 15 min and 
stored at −20°C until analysis. Liquid–liquid extraction 
was performed prior to the HPLC analysis. Briefly, the 
plasma (100 µl) was mixed with dichloromethane-meth-
anol (4:1, v/v) on a vortex-mixer for 3 min to extract the 
drug. Upon centrifugation at 10,000 rpm (15,000 g) for 
15 min, the upper aqueous layer was removed by aspi-
ration and the organic layer was transferred to a tube 
and evaporated under nitrogen at 50°C. The residue was 
dissolved in 100 µl of anhydrous methanol by vortex. For 
the HPLC analysis, the C-18 column was used and the 
mobile phase (0.02 M KH
2
PO
4
/CH
3
CN/CH
3
OH = 49:17:34 
v/v/v) was delivered at a rate of 1 ml/min. Sample (20 μl) 
was injected and the column effluent was detected with 
a UV detector at 232 nm. The main pharmacokinetic 
parameters were calculated by DAS 1.0 (Anhui, China) 
program.
Bioavailability (BA) is a measurement of the rate and 
extent of a therapeutically active drug that reaches the 
systemic circulation and is available at the site of action. 
When a medication is administered intravenously, its 
bioavailability is 100%. When the standard consists of 
intravenously administered drug, this is known as relative 
bioavailability (BA
R
). The BA
R
 of PA/EPI after administra-
tion was calculated using the following formula (Sonaje 
et al., 2009):
BA
(AUC ) Dose
(AUC ) Dose
100R
A B
B A
=
×
×
× %( )( )
where AUC is the area under the curve.
Statistical analysis
All data are presented as a mean value with its stand-
ard deviation indicated (mean ± SD). Statistical analysis 
was conducted using the Student’s t-test. Differences 
were considered to be statistically significant when the 
p-values were less than 0.05.
Results and discussion
Characterization of PA
Pullulan has three free hydroxyl groups on each glucose 
unit. It is easy to synthesize hydrophobic pullulan deriva-
tive, PA, by means of replacing the hydroxyl groups of the 
glucose unit with acetate groups. Figure 1 shows FT-IR 
spectra of pullulan and PA, which were similar to our 
previous literature (Zhang et al., 2009). Figure 2 shows 
1H NMR spectra of pullulan and PA in DMSO-d
6
. The 
acetylation degree of PA calculated by 1H NMR method 
was 2.6, which is smaller than 2.7 reported by Zhang et al. 
(2009). Based on our previous report, PA with lower DS 
may form smaller NPs in size. Moreover, Li and Huang 
3500 3000 2500 2000 1500 1000 500
Wavenumber (cm−1)
a
b
Figure 1. FT-IR spectra of PA (a) and pullulan (b).
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(2008) also reported that the smaller size of NPs may be 
in favor of longer circulation time in vivo. Therefore, PA 
with acetylation degree of 2.6 was used to prepare PANs 
and PA/EPI in our study.
Characterization of PANs and PA/EPI
The self-assembled NPs were prepared by solvent dif-
fusion method. This method had several advantages 
such as a rapid and simple preparation procedure, great 
potential for large industrial scale production, and easy 
control of the particle size (Zhang et al., 2009). The size 
and the size distributions of PANs and PA/EPI in distilled 
water were measured by DLS. The morphological char-
acteristics were observed by TEM at the same time. As 
shown in Table 1, the mean diameters of PANs and PA/
EPI were 247.6 ± 34.8 nm and 343.4 ± 87.7 nm, with the 
narrow size distributions (the polydispersity indexes 
(PDI) < 0.3, Figure 3). Under TEM observations (Figure 4), 
PANs and PA/EPI were nearly spherical in shape and uni-
form sized.
ζ potential of NPs in different media
The ζ potentials of PANs and PA/EPI in distilled water 
were −3.353 ± 1.296 mV and −3.297 ± 1.025 mV. To model 
the circulation in vivo, we observed the ζ potentials of 
NPs in 10% FBS, which had a composition very similar 
to the body liquids. The ζ potentials of PANs and PA/EPI 
in 10% FBS were −1.460 ± 0.297 and −1.902 ± 1.112 mV. 
According to the previous report (Levchenko et al., 2002; 
Alexis et al., 2008), neutral NPs would exhibit a decreased 
rate of macrophage phagocytosis system (MPS) uptake. 
However, MPS is the major contributor for the clearance 
of NPs, thus the reducing rate of MPS uptake could be 
considered as the best strategy for prolonging the cir-
culation of NPs (Li & Huang, 2008). Therefore, PA/EPI 
prepared in this study would exhibit the longer blood 
circulation time than free EPI in vivo.
The storage stability of PANs
Stability is an important facet of preparation and a neces-
sary step in the development process, it will indicate the 
potentiality of industry production. The possibilities of 
modulating the loaded drug’s pharmacokinetic param-
eters are dependent on physicochemical properties such 
as stability, size, and surface characteristics (Lourenco 
et al., 1996). PANs dispersions maintained slight opal-
escence within 2 months. As shown in Table 2, the size, 
size distribution, and ζ potential of PANs showed no sig-
nificant changes during 2 months. Therefore, it could be 
concluded that PANs in aqueous media were stable for 
at least 2 month at 4°C. Stabilization of colloidal systems 
is traditionally viewed as arising from either electrostatic 
or steric effects (Lourenco et al., 1996). A ζ potential of at 
least −30 mV for electrostatic stabilized systems is desired 
to obtain a physically stable suspension according to the 
literature (Müller & Jacobs., 2002). The higher zeta poten-
tial value indicates the better stability (Dai et al., 2010). 
The absolute value of ζ potential was lower than 5 mV 
in our study. The result showed that electrostatic stabi-
lization was not provided efficiently in the suspension; 
5.0
a
b
ppm (t1) 4.0 3.0 2.0
Figure 2. 1H NMR spectra of pullulan (a) and PA (b) (DMSO-d6).
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Figure 3. Diameter distributions of PANs (a) and PA/EPI (b).
Table 1. Size and PDI of PANs and PA/EPI (  ± s, n = 6).
NPs Diameter (nm) PDI
PANs 247.6 ± 34.8 0.179 ± 0.057
PA/EPI 343.4 ± 87.7 0.195 ± 0.069
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therefore, a steric stabilization may occur and provide the 
stability of the PANs. It may also be important information 
for developing a new nanosuspension liquid formulation 
about pullulan acetate.
In vivo toxicity
To evaluate whether i.v. administration (at dose of 
200 mg/kg) of PANs was associated with any toxicity in 
vivo, animals were treated with a single dose of empty 
NPs. No significant differences between the PANs group 
and the control group in clinical signs, e.g. diarrhea, fever, 
and other systemic symptoms, and no mortality occurred 
throughout the entire study course. Additionally, there 
were no significant differences in body weight and food 
intake for both male and female mice between the two 
studied groups (Tables 3 and 4). Figure 5 shows the 
microscopic examination of major organs including 
heart, liver, spleen, lung, and kidney sections stained with 
H&E. Pathological changes in the major organs including 
heart, liver, spleen, lung, kidney, stomach, and intestinal 
segments were scarcely observed at 15 days. Moreover, 
no evidence of inflammatory reactions was observed in 
the experimental group. All the above results indicated 
that no apparent toxicity of the PANs was found in the 
experimental animals after i.v. at a dose of 200 mg/kg.
In vivo pharmacokinetics
The plasma levels of EPI were determined following a sin-
gle i.v. injection of EPI or PA/EPI (10 mg/kg EPI equiv.) in 
female Wistar rats. The plasma levels over 48 h are shown 
in Figure 6 and the PK parameters are summarized in 
Table 5. The peak concentration of total EPI in plasma was 
14.65 mg/L at 1 min after injection and then decreased to 
nearly undetectable levels after 24 h. The maximum con-
centration (C
max
) of PA/EPI at 5 min was 9.80 mg/L, which 
was obviously lower than that of EPI because of sustained 
release from NPs. According to the previous report (Mross 
et al., 1988; Jakobsen et al., 1991; 1994), free EPI rapidly 
Table 2. Diameter and ζ potential of PANs (  ± s, n = 3).
Time Diameter (nm) PDI ζ potential (mV)
Day 0 260.4 ± 8.03 0.180 ± 0.025 −3.353 ± 1.296
1 month 242.4 ± 27.15 0.162 ± 0.073 −2.058 ± 1.987
2 month 229.5 ± 17.78 0.136 ± 0.085 −1.580 ± 2.153
Table 3. Body weight of PANs i.v. injected in mice at 200 mg/kg dose 
(  ± s, g).
Group Sex n Day 1 Day 8 Day 15
Control 5 18.46 ± 0.81 23.12 ± 1.51 24.90 ± 1.04
5 18.64 ± 1.17 25.68 ± 2.81 30.02 ± 2.25
PANs 5 18.14 ± 0.68 22.85 ± 1.12 24.96 ± 0.88
5 18.68 ± 0.51 26.30 ± 0.80 30.06 ± 1.48
Table 4. Food intake of PANs i.v. injected in mice at 200 mg/kg dose 
( , g).
Group Sex n Day 8 Day 15
Control 5 4.97 5.12
5 5.62 6.50
PANs 5 4.57 5.26
5 5.53 6.40
a b
Liver
Spleen
Kidney
Lung
Heart
Figure 5. Representative photomicrographs of the heart, liver, spleen, 
lung, and kidney sections (H&E staining) of mice of control group (a) 
and treated with test NPs (b).
a
100 nm 0.2 µm
b
Figure 4. Transmission electron micrographs (TEM) of (a) PANs and 
(b) PA/EPI.
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disappeared from the circulation due to its short half-life. 
In this study, the terminal elimination half-life of free EPI 
was 8.129 h (Table 5), which was consistent with that of 
7.3 h of doxorubucin (Gustafson et al., 2002; Bibby et al., 
2005). In contrast, PA/EPI showed a much longer circula-
tion time and its elimination half-life time was 17.231 h, 
2.12-times that of free EPI. The clearance of EPI loaded in 
NPs was 0.104 L/h, which is 3.16-times smaller than free 
EPI. Moreover, the mean residence time (MRT) of PA/
EPI in the plasma was 15.854 h, 1.9-times that of free EPI. 
Altogether, PA/EPI had the longer t
1/2
 and MRT, lower V
d
 
and CL than the free drug in rats. At the same time, the 
AUC of EPI and PA/EPI from 0–24 h were 48,128.269 and 
91,006.508 µg h/L, respectively. The bioavailability of free 
EPI was 100%, the BA
R
 of PA/EPI calculated through the 
equation above by the AUC
0–24h
 was 189%, much higher 
than the free drug. According to the previous report (Li 
& Huang, 2008), we believed that the longer t
1/2
 of PA/EPI 
in plasma may be due to its low ζ potential and moder-
ate size. As prolonged plasma circulation is the driving 
force for increased tumor targeting (Seymour et al., 1995), 
Tsuchihashi et al. (1999) prepared long circulating lipo-
somes to improve therapeutic efficacy of doxorubicin. 
In this study, the slow release of EPI from PANs in the 
blood suggested that the bioavailability of EPI improved 
when it was loaded into PANs. However, whether it could 
enhance the uptake of passive permeability in targeting 
tumor tissues or not needs to be further proved by the 
experiments such as bio-distribution study and pharma-
codynamic test.
Conclusions
In this study, PA with the DS of 2.6 was synthesized and 
characterized. PANs and PA/EPI with moderate size and 
low potential were prepared by the solvent diffusion 
method. The nanoparticles were stable in aqueous media 
for at least 2 months in vitro, furthermore, PANs were safe 
in mice at 200 mg/kg and showed the potential to improve 
the bioavailability of the loaded drug in vivo.
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